Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

Yousef Zakharia, MD, medical oncologist, associate professor of medicine, the University of Iowa, the University of Iowa Hospitals and Clinics, discusses the real-world treatment outcomes of first-line axitinib (Inlyta) plus pembrolizumab (Keytruda) in patients with advanced renal cell carcinoma (RCC) based on International Metastatic RCC Database Consortium (IMDC) risk score.